Supercharge Your Innovation With Domain-Expert AI Agents!

A kind of anticoagulant small molecule compound and its application and medicine containing it

A small molecular compound and small molecule technology, applied in the preparation of prevention and treatment of thrombotic diseases, in the field of anticoagulant polypeptides, can solve the problems of narrow drug treatment window, easy to cause bleeding complications, etc., achieve small bleeding side effects, Prolong the thromboplastin time and have obvious antithrombotic effect

Active Publication Date: 2022-03-29
深圳市龙华区中心医院
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Whether it is traditional blood coagulation drugs such as warfarin and heparin or FXa inhibitors (rivaroxaban, apixaban, etc.) Although new drugs such as dabitran etexilate and hirudin have good blood coagulation effects, they all have a fatal deficiency. The drug treatment window is relatively narrow, which easily causes bleeding complications.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of anticoagulant small molecule compound and its application and medicine containing it
  • A kind of anticoagulant small molecule compound and its application and medicine containing it
  • A kind of anticoagulant small molecule compound and its application and medicine containing it

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] The synthetic equation of the anticoagulant small molecular compound that selectively inhibits blood coagulation factor XIa is as follows:

[0039]

[0040] The synthesis steps of the anticoagulant small molecules include:

[0041] Will with CH 2 (COOH) 2 According to the molar ratio of 1:1.1, the reaction is carried out at 76 degrees Celsius to obtain then With ethanol according to the molar ratio of 1:1, react under the condition of 76 degrees Celsius to get

[0042] 2) Will According to the molar ratio of 1:22 with thionyl chloride, react under the condition of 79 degrees Celsius to obtain

[0043] 3) The obtained in step 1) and obtained in step 2) According to the molar ratio of 1:1, the reaction is carried out at 0 degrees Celsius to obtain

Embodiment 2

[0045] Anticoagulant activity of the anticoagulant small molecular compound provided by the invention

[0046] The anticoagulant activity of the anticoagulant small molecular compound provided by the invention is observed by detecting activated partial thromboplastin time (aPTT) and prothrombin time (PT).

[0047] Determination of prothrombin time (PT): prepare 1 part of anticoagulant small molecule compound with different concentrations and 4 parts of normal human plasma, mix well and incubate at 37°C for 15 minutes, then use a coagulation instrument S5100 (SYSMEX, Japan), and set the measurement parameters as follows: mix Plasma 50ul+50ul original aPTT reagent+50ul original calcium chloride reagent. The instrument reads the result. Each concentration was repeated twice, and the average value was taken. Experimental results such as figure 1 shown.

[0048] Determination of prothrombin time (PT): prepare 1 part of anticoagulant small molecule compound with different concen...

Embodiment 3

[0052] Effects of Anticoagulant Small Molecular Compounds on Coagulation Time in Rats

[0053] 40 SPF grade SD rats (provided by the Experimental Animal Center of Guangdong Medical University), body weight 250 ± 50g, were randomly divided into 4 groups, respectively blank control group (distilled water), anticoagulant small molecule low dose group (20mg / kg), Anticoagulant small molecule medium dose group (40mg / kg) and anticoagulant small molecule high dose group (80mg / kg), 10 rats in each group. Rats were intragastrically administered, and after 3 hours, blood was taken from the tail vein or eyeballs, injected into a plastic tube added with 3.8% sodium citrate (blood: anticoagulant = 9:1), and shaken gently. Centrifuge at 1500Xg for 10min to separate the plasma. Determination of aPTT and PT, the measurement method is as described in (2). The results are shown in Table 1

[0054] the result shows

[0055] Anticoagulant small molecule compounds can significantly prolong plas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an anticoagulant small molecule compound and its application and medicine containing it. The structural formula of the anticoagulant small molecule compound is that the anticoagulant small molecule compound can selectively inhibit blood coagulation factor XIa, and has strong anticoagulant Coagulation activity can significantly prolong plasma activated partial thrombin time, but has little effect on prothrombin time and has no effect on thrombin time. The small molecule has a strong antithrombotic effect, can be orally absorbed, and can be used as an oral medicine for the prevention and treatment of thrombotic diseases, and has little side effect.

Description

technical field [0001] The invention belongs to the field of biomedicine. Specifically, the present invention relates to a class of anticoagulant polypeptides and the application of the anticoagulant polypeptides in the prevention and treatment of thrombotic diseases. Background technique [0002] At present, the most important and common complication in the prevention and treatment of clinical antithrombotic drugs is bleeding. Therefore, there is a very urgent clinical need to find effective anticoagulant and antithrombotic drugs with low bleeding risk. In recent years, through clinical research on hemophilia C (FXI deficiency syndrome), animal experiments of knocking out FXI gene and antithrombotic experiments of FXIa inhibitors have shown that: FXI, as a new target for antithrombotic prevention and treatment, has a wide window of drug treatment and anti-hemorrhage The side effects are small, but the current research on fXIa inhibitors as new drugs has only recently recei...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D235/06C07D261/20A61K31/4184A61K31/423A61P7/02
CPCA61P7/02C07D235/06C07D261/20
Inventor 李少金肖水秀张肄鹏邵正梁旭玲杨宜球何小奇
Owner 深圳市龙华区中心医院
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com